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Abstracts: Introduction: Many attempts have been undertaken for surgical correction of congenital heart defects. 
Reconstruction of the right ventricular outflow tract (RVOT) is a main component of many procedures. Homograft 
devices are considered as benchmark, but these are in short supply. Xenografts and tissue engineered heart valves 
(TEHV) have been proposed as solution. This review aims to explore what progress has been made for these two 
alternatives.  
Methods: A systematic search for TEHV and the commonly used xenograft (Matrix P / P+, Shelhigh and Contegra) 
devices through ISI web of Knowledge was performed. The SynerGraft homograft was also included.  
Results: Contegra, Shelhigh and Matrix P / Matrix P+ have been used with varying success. The problems are foreign 
body reaction, with inflammation, stenosis of the conduit or more distally in the pulmonary arteries and regurgitation. In 
spite of efforts during more than 20 years, TEHV has not left the laboratory: there is still an ongoing search for the ideal 
scaffold, adequate cell sources for cellular repopulation and culture media. There are no long-term animal models for the 
latter device.  
Conclusions: To treat patients with congenital heart disease, reconstruction can be performed with xenograft devices, 
but their limitations have to be taken into account. Matrix P and P+ as well as Shelhigh suffer from inflammation with 
stenosis. The alternative, TEHV, will not be available for the foreseeable future. In any case, any TEHV device has to 
compete against more established values.  
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INTRODUCTION 
The treatment of congenital heart disease can be 
performed by repair, reconstruction or replacement of 
valves and outflow tracts, especially at the right side. If 
a valve replacement is needed in such procedures, 
there are two main types of devices: mechanical and 
biological. The most often used contemporary 
mechanical devices are bi-leaflet valves. For biological 
devices, the homograft can be considered as gold 
standard, but these are in limited supply. In contrast, 
porcine xenograft, bovine pericardial and some other 
devices are off the shelf. These devices, however, 
have not the capacity to grow with the patient. A valve 
repair is another approach, but this requires the 
patients’ own tissues of sufficient quality, which is not 
always at hand. For this reason, tissue engineered 
heart valves (TEHV) are under development. These 
constructs are designed to avoid deterioration (which is 
the main complication of a biological prosthesis) or 
thromboembolic events (which is the main complication 
of mechanical valves) [1]. Moreover, implantation of a 
living device should, make in-vivo repair after 
implantation possible. The TEHV under development 
are 1) decellularized biological matrices, with or without 
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reseeding, 2) fibrin based scaffolds and 3) 
biodegradable synthetic scaffolds with reseeding [2].  
Before 2005, there were no published results of 
bioresorbable matrices in patients. These devices are 
considered as being not biomimetic [3]. Also, negative 
results tended not to be published. Hybrid approaches 
with collagen, completed with glycosaminoglycans and 
elastin did produce publications, however. Before 2005, 
its standardization was still ongoing [2]. The use of a-
cellular matrices were also unsuccessful, since these 
do not “revitalize” [4]. Moreover, the use of the CryoLife 
Synergraft, a decellularized xenograft at that time, 
resulted in disaster and was withdrawn [5]. A more 
recent review discussed the use of biodegradable 
scaffolds, cell seeding, maturing in bioreactors and 
implantation of a-cellular devices [6]. In vivo studies, 
however, remained few in number and all are of short-
term duration. As alternative, some devices with 
xenogeneic origin have been developed. Sometimes, 
these are also called TEHV since these underwent 
some processing. One could wonder if decellularization 
process suffices to label this as TEHV. The research 
question for this review can be formulated as: “What 
are the results of four of the most commonly used 
commercially available devices in the repair and 
reconstruction of congenital heart defects” and “What 
has been the progress in development of TEHV in the 
period 2010-2014”.  
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METHODS 
A systematic review of literature was performed 
using “ISI web of knowledge” database, for a 5-year 
time span between 2010 and 2014. For the first track, 
the search terms were “Tissue Engineered Heart Valve 
AND pediatr* OR paediatr*”. The items of interest were 
the matrices, either synthetic of biologic, the cell 
sources for repopulation, the culturing conditions, and 
in case of animal studies, the hemodynamic in vivo and 
immune-histochemical data after explantation. For the 
second track, the search terms included “Contegra 
AND right ventricular”, “Shelhigh AND right ventricular”, 
“Synergraft AND right ventricular”, “Matrix P and right 
ventricular” as decellularized devices most in use. The 
items of interest were the grafts themselves, the 
indication for operation, age at operation, hospital 
mortality, duration of follow-up, freedom of mortality, 
dysfunction and failure, mean transvalvular gradient 
across the pulmonary valve, pulmonary valve 
regurgitation over 2/4, re-intervention and reoperation 
rate. Reviews, state-to-the-art papers and papers not 
concerning the topic were excluded.  
RESULTS 
The search for the first track resulted in 29 
manuscripts. There were fourteen reviews, three 
papers were about other issues, and remarkably, two 
papers, dealing with the Matrix P device [7,8] 
overlapped with track 2. Of the remaining ten papers, 
seven were “in vitro” experiments and three were “in-
vivo” animal studies. The “in-vitro” papers dealt with 
several topics: decellularization of a porcine root [9], 
assembling tri-layered scaffolds by electrospinning [10], 
self-assembling of a tri-leaflet valve [11], use of fibrin 
with a valve-like mechanical conditioning structure [12], 
the rate of degradation of different types of synthetic 
scaffolds with respect to deposition of new matrix 
proteins and the mechanical properties [13], culturing 
of valve interstitial cells on synthetic scaffolds [14], and 
the use of prenatally harvested cells from umbilical 
blood and of amniotic fluid or chorionic villi [15]. The 
parameters under investigation were a) microscopy to 
detect inflammation or fibrosis, b) immunoh- 
istochemistry to identify the different cell types, c) 
biochemistry to identify the different types of collagen, 
of glycosaminoglycans and of DNA, d) gene 
expression, e) transmission electron microscopy as 
well as f) anisotropic biomechanical properties. The “in-
vivo” papers dealt with spontaneous in-vivo 
regeneration of decellularized in pigs [16], comparison 
of cell sources (endothelial, smooth muscle and bone 
marrow) with respect to inflammation, calcification and 
hemodynamic parameters after percutaneous 
implantation in sheep [17], and comparison of the effect 
of two types of culture mediums on recellularization 
and the potential contractile activity of the reseeded 
cells [18]. The parameters under investigation were 
hemodynamics in vivo and immunohistochemistry or 
transmission electron microscopy after explantation.  
The search for the second track resulted in 33 
manuscripts concerning decellularized devices. These 
were explored for their demographic, clinical and 
hemodynamic results (Table). Most papers were 
description of the results of one device. The SynerGraft 
has been included as an example of homograft. Earlier 
implantations of xenogeneic SynerGraft devices [5] had 
disastrous results. Decellullarized SynerGraft 
homograft seems less immunogenic and therefore 
more durable than the standard homograft for RVOT 
reconstruction in patients with mean age of 18 years. It 
is considered as superior for the Ross procedure in 
aortic valve replacement in terms of dysfunction, failure 
(defined as peak transvalvular gradient of over 40 
mmHg or pulmonary valve regurgitation of more than 
grade 2) and explantation [19-21]. However, longer 
follow-up duration is needed to establish its durability. 
Some consider the advantages as “not significant” and 
hence the additional costs not justified [22]. The 
decellularized pulmonary homograft seeded with 
autologous endothelial cells in a small series of 
younger adults showed good clinical and hemodynamic 
results, with absence of calcification at 10 years [23]. 
This device could be considered as real tissue 
engineering because of the cell seeding. Decellularized 
fresh pulmonary homograft had better results in terms 
of reoperations and hemodynamics compared to 
glutaraldehyde fixed bovine jugular vein (BJV) or 
cryopreserved homograft. An adaptive growth has 
been observed in the former [24]. 
The Matrix P / P+ conduit is a glutararaldehyde-free 
decellularized porcine conduit with valve and cell free 
pericardial patch mounted on a stent. These devices 
could be considered as TEHV, with a presumed 
capacity for growth. Matrix P and Matrix P+ devices for 
reconstruction of the RVOT failed early in the very 
young, mostly due to inflammation with subsequent 
stenosis: freedom of failure at two years was about 
60%. Autologous cell seeding in the explanted 
specimens was poor [7] and endothelial cell-ling was 
absent [8]. The inflammation was described as massive 
and of foreign-body type with infiltration by B and T 
cells, as well as macrophages and extensive fibrosis 
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Table 1: Valve Type, Demographic Data, in-Hospital Results and Long-Term Results 
REF Device  n Indication Age H-mort (%)  FU(y)  y Mort  Dysf   Fail  mTVG PI>2 Reint Reop 
[7] Matrix P / P+  93 RVOT  20 4.3 1 2 - - 22.6 39.8 - 4 27% 
[19] standard 61 RVOT  18.6  5.7 - 13%* 48% 32% - 32%  22% 
 decell SG 39 “  “  5.8 - 10%*  26% 13% - 10%  - 8% 
20] standard 29 Ross AVR 28.6 0 4.9 - 0 0 - 12 0 - 37(8) 
 decell SG  34 “ “ 0 “ - 0 0 - 12 0 - 21(8) 
[21] conventional 665 Ross 28.3 3.9 3.7 5 5.2 - 3.7 - - 4.5 5.6% 
 conventional 581 RVOT  5.2 8.4 3.7 5 15.4 - 10.7 - - 10.5 8.6% 
 decell SG 193 Ross 32.4 1.6 4.0 5 3.1 - 6.1 - - 5.6 3.0% 
 decell SG 581 RVOT 13.4 2.7 4.0 5 7.7 - 6.6 - - 7.3 2.4% 
[22] standard 47  9.9   8 2% - 22 
(10) 
- 37%  13/47 12/47 
 decell SG 47  9.9   8 4% - 16 
(25) 
- 21%  9/47 9/47 
[26] Matrix 61 RVOT 7 8.2  3 - 13 - - - 9/62 4/62 
[27] Matrix P+ 16 RVOT 14 0 0.8 1 - - - 66 - - 38% 
[28] Contegra 244 RVOT 4.7 0.8  1 5.3% - - - - - 3.7% 
       5 7.2% - - - - - 20.7% 
       7 10.0% - - - - - 35.8% 
       10 10.0% - - - - - 62.9% 
 homografts 135 “  1.7 2.2 3.7 1 9.6% - - - - - 5.4% 
       5 10.5% - - - - - 24.3% 
       7 10.5% - - - - - 31.4% 
       10 13.2% - - - - - 41.7% 
 
[29] Contegra 106 Ross 
&RVOT 
13 3/106 7.6 7 4.3% - - - - - - 
[30] Homograft 62 RVOT <1   5 - 14.6% - - 8.3% - 30.6% 
       10 - 40.8% - - 35.2% - - 
 Contegra 35 “ <1   5 - 24.9% - - 26.4% - 40.6% 
       10 - 64.2% - - 55.8% - - 
 Hancock-porc 48 “ <1   5 - 30.9% - - 13.1% - 46.2% 
       10 - 50.3% - - 47.9% - - 
[31] Contegra 18 RVOT 9 16.7% 2 - - 2/15 - 50 2/15 2/15 - 
[32] ven homogr 20 RVOT    ) comparable concerning catheter intervention, reoperation 
or either 
 valve homogr 16 “   )  comparable concerning catheter intervention, reoperation 
or either 
[33] Four types 56 RVOT  14.2% 1.8 - 1/44 - 15/44 26-67 - 3/44 - 
[34] Contegra 16 CHD  3/16  - - - 1/12 - - 1/12 2/12 
[35] TA repair 19 RVOT 0,2 21.1% 1.8 - - 6/15 - - 0 4/15 - 
[36] Contegra 34 RVOT 10.9 0 7.1 11.4 - - - 19.6 8-27 - 6% 
[37] Contegra 156   7% 4.8 8 10.1% 15.1% - 18.7 25/145 - 13/145 
[38] Contegra 193 RVOT-Ross 6.7 NA 4.6  2.6% - - - - 5.2% 2.6% 
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       10 - - 10% - - - - 
 
[39] All 286 RVOT 5.9 2.7%          
 homograft 88     - - - - 14-
13** 
3 - benchm
ark 
 Monocusps 67     - - - - 16-18 5 - -13% 
 Bicuspid 44     - - - - 46 2 - +78% 
 Contegra 40     - - - - 18-36 3 - +59% 
[40] Homogr comp 66  6.4 0 9.4 9 - - - 12.6 3.4% - 14.3% 
 Homogr 
incomp 
54  “ 0 9.4 9 - - - “ “ - 37.0% 
 Contegra 85  4.8 2* 5.3 9 - - - 14.2 7.2% - 11.0% 
[41] All devices 167 RVOT  17% 6.5 (3.5) - - - - - - 22.1% 
[42] Shelhigh 57 RVOT 18 4 3.1 2 - - - 76 - - 18% 
 Contegra 43 RVOT 4.5 8 5.7 2 - - - 69 - - 9% 
[43] Contegra 54 RVOT 10.4  6.0 1 - - - - - - 1.9% 
       5 - - - - - - 22.7% 
       10 - - - - - - 36.5% 
 Homograft 293 RVOT 13.4  5.9 1 - - - - - - 0.4% 
       5 - - - - - - 6.0% 
       10 - - - - - - 18.6% 
AVR: aortic valve replacement; comp: blood group compatible homograft; decell: decellularized; dysf : dysfunction ; fail : failure; FU: mean follow-up time for the 
group; hosp mort: hospital mortality; incomp: blood group incompatible homograft; mTVG : mean transvalvular gradient; n: number; PI : pulmonary valve insufficiency; 
reinterv: re-intervention; reop: reoperation;  RVOT: right ventricular outflow tract; SG: SynerGraft; ven homogr: venous homograft; TA: truncus arteriosus; y: years  
referring to freedom of  mortality, of dysfunction, of failure, or re-intervention or reoperation. 
* death not graft related;  ** first value children >1 y;  second: infants; definition of dysfunction; mean TVG > 30 mmHg;  definition of failure: mean TVG > 40.  
[8, 25]. Others, however reported results 
comparable to other commonly used devices, with a 3-
year freedom of re-intervention rate of 87% [26]. 
However, early failures of this so-called tissue 
engineered pulmonary device, implanted in mostly 
teenagers warrants caution [27]. Incomplete 
decellularization could contribute to an increased 
immunogenicity [25].  
The Contegra device is a glutaraldehyde fixed 
bovine jugular (BJV) construct containing a valve. The 
Contegra for repair of the RVOT (right ventricular 
outflow tract) is more prone to bacterial endocarditis, 
conduit deterioration and reoperation at mid-term in 
infants compared to the homograft devices. Predictors 
for re-replacement were endocarditis and age of less 
than 3 years at first implantation [28, 29]. Durability for 
the Contegra device seems comparable to that of 
homografts and porcine valved Dacron constructs in 
infants, but implantation during the neonatal period or 
in heterotopic position decreases its durability. 
Moderate stenosis and regurgitation occurs sooner 
[30]. Tetralogy of Fallot as indication, systemic-to-
pulmonary shunt and hypothermia were identified as 
predictors for these events. The treatment of 
endocarditis, which occurs in 11.3-12.5% of the 
patients is surgical [29]. Use of the Contegra device in 
cases with pulmonary atresia, ventricular septal defect 
combined with hypoplastic pulmonary arteries [31] as 
well as for the Fontan procedure should also be 
considered with caution. Valved femoral homograft 
devices could be considered as attractive alternative in 
neonates who need reconstruction of the RVOT [32]. 
Some authors report an acceptable outcome, with 
occurrence of mild-to-moderate stenosis in 40-50% of 
the cases. This can often be treated by catheter based 
intervention. Anyway, long-term results need to be 
awaited [33-36]. Contegra device for RVOT 
reconstruction has acceptable results, but reoperation 
is more common due to small size, which can be 
related to young age and expected patient growth. 
However, there is a freedom from calcification and an 
only moderate increase in mean transvalvular gradient 
from 10 to 19 mm Hg [37, 38]. The Contegra device 
can be considered as valid alternative for pulmonary 
homograft devices [38]. A homograft, however has 
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50% lower rate of reoperation [39], unless this 
homograft is non blood group compatible. A Contegra 
could be a valuable alternative if a compatible 
homograft cannot be found [4], however need for 
intervention because of failure caused by conduit 
stenosis must be anticipated [38].  
Some papers compared the results between several 
devices. In one manuscript, the Shelhigh was 
compared with Contegra, Cryolife, Aortech and some 
less often used devices. These implants were used for 
a variety of indications. The hospital mortality (17%) 
and need for reoperation (22%) were high. The Cryolife 
and Shelhigh implants had the shortest re-operation 
time. The Contegra performed better [41]. In another 
comparison between Shelhigh and Contegra, this was 
confirmed: Shelhigh failed more rapidly and strongly. 
The most prominent indication for implantation was the 
tetralogy of Fallot. For both devices inflammation with 
subsequent stenosis was the predominant mechanism. 
Mean time for reoperation was 1.5y for the Shelhigh 
group and 3.5y for the Contegra group for patients with 
a mean age of 12y. No predictors for failure could be 
identified. However, endocarditis was more common 
with Contegra: 7% versus 1.8% for Shelhigh [42]. The 
higher incidence of endocarditis was also confirmed in 
a comparison between homograft devices and the 
Contegra device. Furthermore, the predictors for re-
replacement were small size, young age, heterotopic 
position and use of Contegra – twice as much 
compared to homograft [43].  
DISCUSSION 
There are several options for the surgical treatment 
of congenital heart defects. These are homograft, 
xenograft and TEHV devices. Although considered as 
superior, homograft devices are in short supply, 
especially for the smaller sizes, needed for the repair of 
such defects. The results seem even better if these 
homograft devices are decellularized [19] and if these 
are blood group compatible [40]. An excellent animal 
(ovine) model, in which the RVOT was reconstructed, 
showed the superiority of pulmonary homograft over an 
aortic homograft and certainly over porcine xenografts: 
after six months the devices were explanted. The 
pulmonary homograft showed little or no calcification. 
There was some calcification in the aortic homograft 
and much more in the porcine devices [44]. The lack of 
homograft devices, especially those of small size, 
leaves the two options, namely TEHV and xenografts. 
The difference between both options must clearly be 
established. In two papers [7, 8], the Matrix P / P+ is 
called a tissue engineered heart valve. However, one 
could wonder if decellularizing a tissue, with the hope 
of repopulation by host cells after implantation is 
enough to call this tissue engineering. A possible 
definition given in 2002 states the following “The 
application of principles and methods of engineering 
and life sciences to obtain a fundamental 
understanding of structure-function relationships in 
novel and pathological mammalian tissues and the 
development of biological substitutes to restore, 
maintain or improve tissue function” [45]. It seems, that 
in practice, the Matrix device falls short of this 
definition.  
The first option, TEHV shows some peculiarities: at 
least half of the papers recently published about TEHV 
in pediatric cardiac cardiology are reviews. Most of the 
research papers deal with “in-vitro” studies [9-15], 
which seem all promising. But it has become clear that, 
after more than 20 years of research, it remains a 
promise: the ideal matrix (biological or synthetic origin) 
still has to be developed and the ideal cell source or 
sources still have to be identified. Work on the most 
appropriate culture mediums and biomechanical 
conditions is also unfinished. One could wonder if the 
“silver bullet” is ever to be found. Only three papers 
deal with short-term animal studies [16-18]. A fourth, 
comparative study also lasted only 6 months [44]. 
Some results seem promising concerning repopulation 
by cells of the host, absence of fibrosis, inflammation 
thrombosis and stenosis or regurgitation. The main 
limitation, however, is the short duration of the 
experiments, which is three to 15 months. Furthermore, 
not much has been written on the changes of the 
implanted devices within the living animal. Last but not 
least, companies are not inclined to introduce uncertain 
devices which, on the one hand, have to compete with 
established values with a predictable outcome, and on 
the other hand, could lead to disaster. 
Every device within the second option has its own 
problems. Two papers of the first track [7, 8] and 
another of the second track [27] deal with the Matrix P 
and P+ device. The results warrant caution in its use. 
The Contegra shows acceptable results, but 
endocarditis has been repeatedly identified as a 
problem [28, 29, 42]. The Shelhigh device is 
susceptible to a quicker and stronger inflammatory 
response which leads to fibrosis and stenosis [41, 42].  
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CONCLUSIONS 
Congenital heart disease is a difficult problem to 
treat. For the moment, the use of homograft devices 
seem to be the best option. Because these are in short 
supply, xenografts have been used as an alternative. 
Most of these xenografts have their specific problems: 
inflammation and rapid failure for the Shelhigh and 
Matrix P / P+ and endocarditis for the Contegra. These 
devices show no somatic growth. A second alternative, 
the use of tissue engineered devices is for this moment 
purely theoretical. Although efforts to develop a viable 
product which theoretically can grow with the patient, 
are ongoing for 20 to 30 years, it is still in the laboratory 
stage. Animal experiments are few, all with a short 
follow-up. Methods to evaluate the in-vivo changes of 
such devices in living animals are still lacking. Even if 
an tissue engineered device would be available today, 
it would still have to prove its time-consuming claims 
against the existing devices.  
LIMITATIONS 
There are several limitations in this manuscript. 
First, there is a wide variety in congenital heart defects. 
Little attention has been paid to this aspect. 
Nevertheless, one major observation can be made: 
heterotopic implantation of a device leads to worse 
results. Second, only the most commonly used 
xenografts have been included. Although this may be 
arbitrary, their results can be considered as 
representative. Third, the manuscripts included have 
different designs. Some are retrospective, others are 
prospective. Still others are experimental, in-vivo as 
well as in-vitro. This precludes any quantitative 
analysis. Fourth, there was no quality control of the 
manuscripts included. This might have one advantage: 
their results represents, the “real life”, also outside the 
Western world.  
ACKNOWLEDGEMENTS 
None 
CONFLICTS OF INTERESTS  
None to declare 
REFERENCES 
[1] Stassano P, Di tommaso L, Monaco M, et al. Aortic valve 
replacement. A prospective randomized evaluation of 
mechanical versus biological valves in patients ages 
between 55 and 70 years. J Am Coll Cardiol 2009; 54: 1862-
1868. 
http://dx.doi.org/10.1016/j.jacc.2009.07.032 
[2] Veseli I. Heart Valve Tissue Engineering. Circ Res 2005; 97: 
743-755.  
http://dx.doi.org/10.1161/01.RES.0000185326.04010.9f 
[3] Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive 
extracellular microenvironments for morphogenesis in tissue 
engineering. Nat Biotechnol. 2005; 23: 47-55. 
http://dx.doi.org/10.1038/nbt1055 
[4] Hilbert S, Yanagida R, Krueger P, et al. A comparison of the 
explant pathology findings of anionic and nonionic detergent 
decellularized heart valve conduits. In: Nerem RM, ed. 
Cardiovascular tissue engineering: From basic biology to 
cell-based therapies. Hilton Head, SC: Georgia Institute of 
Technology; 2004: 43.  
[5] Simon P, Kasimir MT, Seebacher G, Weigel G, Ullrich R, 
Salzer-Muhar U, et al. Early failure of the tissue engineered 
porcine heart valve SYNERGRAFT in pediatric patients. Eur 
J Cardiothorac Surg. 2003; 23: 1002–1006; discussion 1006. 
http://dx.doi.org/10.1016/S1010-7940(03)00094-0 
[6] Schoen FL. Heart Valve Tissue Engineering, Quo Vadis? 
Curr Opin Biotechnol 2011. 
http://dx.doi.org/10.1016/j.copbio.2011.01.004 
[7] Perri G, Polito A, Espisto C. Early and late failure of tissue-
engineered pulmonary valve conduits used for right 
ventricular outflow tract reconstruction in patients with 
congenital heart disease. Eur J Cardiothorac Surg 2012; 41: 
1320-1325. 
http://dx.doi.org/10.1093/ejcts/ezr221 
[8] Voges I, Braesen JH, Entenmann A. Adverse results of a 
decellularized tissue –engineered pulmonary valve in 
humans assesses with magnetic resonance imaging. Eur J 
Cardiothorac Surg 2013; 44: E272-E279.  
http://dx.doi.org/10.1093/ejcts/ezt328 
[9] Luo J, Korossis SA, Wilshaw SP. Development and 
characterization of acellular porcine pulmonary valve 
scaffolds for tissue engineering. Tissue Engineering PART A 
2014; 20: 2963-2974. 
http://dx.doi.org/10.1089/ten.tea.2013.0573 
[10] Masoumi N, Annabi N, Assmann A. Tri-layered elastomeric 
scaffolds for engineering heart valve leaflets. Biomaterials 
2014; 35: 7774-7785. 
http://dx.doi.org/10.1016/j.biomaterials.2014.04.039 
[11] Dube J, Bourget JM, Gauvin R. Progress in developing a 
living human tissue engineered tri-leaflet heart valve 
produced by the self-assembly approach. Acta Biomat 2014; 
10: 3536-3570.  
http://dx.doi.org/10.1016/j.actbio.2014.04.033 
[12] Alfonso AR, Rath S, Rafiee P. Glycosaminoglycan 
entrapment by fibrin in engineered heart valve tissues. Acta 
Biomat 2013; 9: 8149-8157.  
http://dx.doi.org/10.1016/j.actbio.2013.06.009 
[13] Sant S, Iyer D, Gaharwar AK. Effect of biodegradation and 
de novo matrix synthesis on the mechanical properties of 
valvular interstitial cell-seeded polyglycol sebacate-
polycaprolactone scaffolds. Acta Biomat 2013; 9: 5963-5973. 
http://dx.doi.org/10.1016/j.actbio.2012.11.014 
[14] Masoimi N, Johnson KL, Howell MC. Valvular interstitial cell 
seeded poly [glycerol sebacate] scaffolds: towards a 
biomimetic in vitro model for heart valve tissue engineering. 
Acta Biomat 2013; 9: 5974-5988. 
http://dx.doi.org/10.1016/j.actbio.2013.01.001 
[15] Weber B, Zeisberger SM, Hoerstrup SP. Prenatally 
harvested cells for cardiovascular tissue engineering: 
fabrication of autologous implants prior to birth. Placenta 
2011; 32(suppl4); S316-S319.  
[16] Iop L, Bonetti A, Naso P. Decellularized allogeneic heart 
valves demonstrate self-regeneration potential after a long-
Difficulties in Tissue Engineering Heart Valve International Journal of Cardiology and Lipidology Research, 2015, Vol. 2, No. 2    7 
term preclinical evaluation. PLOS ONE 2014; 9: e99593.  
[17] Boldt J, Lutter G, Pohanke J. Percutaneous tissue-
engineered pulmonary valved stent implantation: comparison 
of bone marrow-derived CD133+cells and cells obtained from 
carotid artery. Tissue Eng PART-C Methods 2013; 19: 363-
374. 
http://dx.doi.org/10.1089/ten.tec.2012.0078 
[18] Syedain ZH, Bradee AR, Kren S. Decellularized tissue-
engineered heart valve leaflets with recellularization 
potential. Tissue Eng PART A 2013; 19: 759-769. 
http://dx.doi.org/10.1089/ten.tea.2012.0365 
[19] Ruzmetov M, Shah JJ, Geiss DM, Fortuna RS. 
Decellularized versus standard cryopreserved valve 
allografts for right ventricular outflow tract reconstruction: A 
single-institution comparison. J Thorac Cardiovasc Surg 
2012; 143: 543-549.  
http://dx.doi.org/10.1016/j.jtcvs.2011.12.032 
[20] Brown JW, Ruzmetov M, Eltayeb O, Rodefeld MD, Turrentine 
MW. Performance of Synergraft decellularized pulmonary 
homograft in patients undergoing a Ross procedure Ann 
Thorac Surg 2011; 91: 416-422. 
http://dx.doi.org/10.1016/j.athoracsur.2010.10.069 
[21] Brown JW, Elkins RC, Clarke DR, et al. Performance of the 
CryoValve* SG human decellularized pulmonary valve in 342 
patients relative to the conventional CryoValve at a mean 
follow-up of four years. J Thorac Cardiovasc Surg 2010; 139: 
339-348.  
http://dx.doi.org/10.1016/j.jtcvs.2009.04.065 
[22] Burch PT, Kaza AK, Lambert LA, Holubkov R, Shaddy RE, 
Hawkins JA. Clinical performance of decellularized 
cryopreserved valved allografts compared with standard 
allografts in the right ventricular outflow tract. Ann Thorac 
Surg 2010; 90: 1301-1305.  
http://dx.doi.org/10.1016/j.athoracsur.2010.05.024 
[23] Dohmen PM, Lembcke, Holinski S, Pruss A, Konertz. Ten 
years of clinical results with a tissue-engineered pulmonary 
valve. Ann Thorac Surg 2011; 92: 1308-1314. 
http://dx.doi.org/10.1016/j.athoracsur.2011.06.009 
[24] Cebotari S, Tudorache I, Ciubotaru A, et al. Use of fresh 
decellularized allografts for pulmonary valve replacement 
may reduce the reoperation rate in children and young 
adults. Circulation 2011; 124: S115-S123.  
[25] Cicha I, Rueffer A, Cesnjevar R, et al. Early obstruction of 
decellularized xenogeneic valves in pediatric patients: 
involvement of inflammatory and fibroproliferative processes. 
Cardiovac Pathol 2011; 20: 222-231. 
http://dx.doi.org/10.1016/j.carpath.2010.04.006 
[26] Konertz W, Angeli E, Tarusinov G, et al. Right 
ventricular outflow tract reconstruction with decellularized 
porcine xenografts in patients with congenital heart disease. 
J Heart Valve Dis 2011; 20: 341-347. 
[27] Rueffer A, Purbojo A, Cicha I, et al. Early failure of 
xenogenous de-cellularised pulmonary valve conduits - a 
word of caution! Eur J Cardio-thorac Surg 2010; 38: 78-85. 
http://dx.doi.org/10.1016/j.ejcts.2010.01.044 
[28] Ugaki S, Rutledge J, Al Aklabi M, Ross DB, Adatia I, 
Rebeyka IM. An increased incidence of conduit endocarditis 
in patients receiving bovine jugular vein grafts compared to 
cryopreserved homograft for right ventricular outflow 
reconstruction. Ann Thorac Surg 2015; 99: 140-146. 
http://dx.doi.org/10.1016/j.athoracsur.2014.08.034 
[29] Albanesi F, Sekarski N, Lambrou D, Von Segesser LK, 
Berdajs DA. Incidence and risk factors for Contegra graft 
infection following right ventricular outflow tract 
reconstruction: long-term results. Eur J Cardio-thorac Surg 
2014; 45: 1070-1074. 
http://dx.doi.org/10.1093/ejcts/ezt579 
[30] Vitanova K, Cleuziou J, Hoerer J, et al. Which type of conduit 
to choose for right ventricular outflow tract reconstruction in 
patients below 1 year of age? Eur J Cardio-thorac Surg. 
2014; 46: 961-966. 
http://dx.doi.org/10.1093/ejcts/ezu080 
[31] Mohsin SS, Siddiqui MT, Shaikh AS, Atiq M, Amanullah M. 
Midterm results of bovine jugular vein conduit for right 
ventricular outflow tract reconstruction. J Pakistan Med Ass 
2013; 63: 1266-1270.  
[32] Schiller O, Sinha P, Zurakowski D, Jonas RA. Reconstruction 
of right ventricular outflow tract in neonates and infants using 
valved cryopreserved femoral vein homografts. J Thorac 
Cardiovasc Surg 2014; 147: 874-879. 
http://dx.doi.org/10.1016/j.jtcvs.2013.11.006 
[33] Karaci AR, Aydemir NA, Harmandar B, et al. Early and 
midterm results of valved conduits used in right ventricular 
outflow tract reconstruction. Turkish J Thorac Cardiovasc 
Surg 2012; 20: 689-698.  
[34] Siddiqui MT, Hasan A, Mohsin S, Hamid M, Amanullah MM. 
Contegra valved conduit in the paediatric population: an 
exciting prospect for right ventricle to pulmonary artery 
reconstruction; Experience and outcomes at Aga Khan 
University. J Pakist Med 2012; 62: 1113-1117. 
http://dx.doi.org/10.5606/tgkdc.dergisi.2012.140 
[35] Karaci AR, Aydemir NA, Sasmazel A, et al. Our experiences 
with the surgical repair of truncus arteriosus: early and mid-
term results. Turkish J Thorac Cardiovasc 2012; 20: 194-199 
http://dx.doi.org/10.5606/tgkdc.dergisi.2012.041 
[36] Sfyridis PG, Avramidis DP, Kirvassilis GV, Zavaropoulos PN, 
Papagiannis JK, Sarris GE. The Contegra [R] valved 
heterograft conduit for right ventricular outflow tract 
reconstruction: A reliable solution. Hellenic J Cardiol 2011; 
52: 501-508.  
[37] Palma G, Mannacio VA, Mastrogiovanni G, et al. Bovine 
valved venous xenograft in pulmonary position: medium term 
evaluation of risk factors for dysfunction and failure after 156 
implants. J Cardiovasc Surg 2011; 52: 285-291.  
[38] Prior N, Alphonso N, Arnold P, et al. Bovine jugular vein 
valved conduit: Up to 10 years follow-up. J thorac Cardiovasc 
Surg 2011; 141: 983-987. 
http://dx.doi.org/10.1016/j.jtcvs.2010.08.037 
[39] Neukamm C, Dohlen G, Lindberg HL, Seem E, Norgard G. 
Eight years of pulmonary valve replacement with a 
suggestion of a promising alternative. Scand Cardiovasc J 
2011; 45: 41-47.  
http://dx.doi.org/10.3109/14017431.2010.519401 
[40] Christenson JT, Sierra J, Manzano NE, et al. Homografts and 
xenografts for right ventricular outflow tract reconstruction: 
Long-term results. Ann Thorac Surg 2010; 90: 1287-1294.  
http://dx.doi.org/10.1016/j.athoracsur.2010.06.078 
[41] Saritas B, Ozkan S, Ozcobanoglu S, Ozkan M, Aslamaci S. 
Use of xenograft conduits in congenital heart disease. 
Turkish J Thorac Cardiovasc Surg 2011; 19: 533-538.  
http://dx.doi.org/10.5606/tgkdc.dergisi.2011.083 
[42] Schoenhoff FS, Loup O, Gahl B, et al. The Contegra bovine 
jugular vein graft versus the Shelhigh pulmonic porcine graft 
for reconstruction of the right ventricular outflow tract: A 
comparative study. J Thorac Cardiovasc Surg 2011; 141: 
654-661.  
http://dx.doi.org/10.1016/j.jtcvs.2010.06.068 
[43] Urso S, Rega F, Meuris B, et al.The Contegra conduit in the 
right ventricular outflow tract is an independent risk factor for 
graft replacement. Eur J Cardio-thorac Surg 2011; 40: 603-
609.  
http://dx.doi.org/10.1016/j.ejcts.2010.11.081 
[44] FlamengW, Jashari R, De Visscher G, Mesure L, Meuris B. 
Calcification of allograft and stentless xenograft valves for 
right ventricular outflow tract reconstruction: An experimental 
study in adolescent sheep J Thorac Cardiovasc Surg 2011; 
141: 1513-1521. 
http://dx.doi.org/10.1016/j.jtcvs.2010.08.082 
8    International Journal of Cardiology and Lipidology Research, 2015, Vol. 2, No. 2 Wilhelm P. Mistiaen 
[45] McIntire LV, Greisler HP, Griffith L, et al. WTEC Panel Report 
on Tissue Engineering Research. Baltimore, Md: Loyola 
College; 2002. 
 
Received on 11-07-2015 Accepted on 09-08-2015 Published on 30-09-2015 
 
http://dx.doi.org/10.15379/2410-2822.2015.02.02.01 
© 2015 Wilhelm P. Mistiaen; Licensee Cosmos Scholars Publishing House. 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, 
provided the work is properly cited.  
 
